Advanced cell programming

An extensive cell programming capability

Engineered T cell immunotherapy products show significant efficacy for hematological malignancies

However, realization of the potential of this approach across a broad range of tumor types will require multiple technology solutions to address limitations of the current generation of therapies.

Our technological approach is the development of advanced T-cell engineering components designed to directly address clinical challenges. A focus on our early-stage pipeline incorporates multiple components in a single product.

Latest Abstracts & Publications

See all
Molecular Therapy
October 05 2023

Large-scale manufacturing of base-edited chimeric antigen receptor T-cells

August 30 2023

CD19/CD22 targeting with co-transduced CAR T-cells to prevent antigen negative relapse after CAR T-cell therapy of B-ALL

Molecular Therapy Methods & Clinical Development
July 14 2023

Detection and quantification of integrated vector copy number by multiplex droplet digital PCR in dual-transduced CAR T cells